S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
NASDAQ:JANX

Janux Therapeutics (JANX) Stock Price, News & Analysis

$51.86
-0.79 (-1.50%)
(As of 04/15/2024 ET)
Today's Range
$50.43
$54.59
50-Day Range
$7.93
$52.65
52-Week Range
$5.65
$58.69
Volume
1.04 million shs
Average Volume
765,370 shs
Market Capitalization
$2.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.60

Janux Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
14.9% Upside
$59.60 Price Target
Short Interest
Bearish
11.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Janux Therapeutics in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.41) to ($1.64) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.73 out of 5 stars

Medical Sector

720th out of 928 stocks

Pharmaceutical Preparations Industry

335th out of 434 stocks

JANX stock logo

About Janux Therapeutics Stock (NASDAQ:JANX)

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

JANX Stock Price History

JANX Stock News Headlines

Janux Therapeutics (NASDAQ:JANX) Shares Gap Up to $44.62
2024 Oil Boom
Wall Street’s betting on new oil bull market… JP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing.
Stocks See Continued Pressure as Bond Yields Climb
2024 Oil Boom
Wall Street’s betting on new oil bull market… JP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing.
Janux Therapeutics Inc Ordinary Shares JANX
Forecasting The Future: 4 Analyst Projections For Janux Therapeutics
See More Headlines
Receive JANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/08/2024
Today
4/15/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:JANX
Fax
N/A
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$59.60
High Stock Price Target
$100.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+14.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-58,290,000.00
Net Margins
-721.18%
Pretax Margin
-721.18%

Debt

Sales & Book Value

Annual Sales
$8.08 million
Book Value
$7.46 per share

Miscellaneous

Free Float
33,372,000
Market Cap
$2.69 billion
Optionable
Optionable
Beta
4.19
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. David Alan Campbell Ph.D. (Age 64)
    President, CEO & Director
    Comp: $852.5k
  • Mr. Byron Robinson J.D. (Age 59)
    Ph.D., Chief Strategy Officer
    Comp: $606.8k
  • Mr. Tighe M. Reardon C.F.A. (Age 47)
    CPA, Acting Chief Financial Officer
  • Mr. Charles M. Winter (Age 55)
    Chief Technical Officer
  • Dr. Tommy Diraimondo Ph.D.
    Chief Scientific Officer
  • Mr. James Pennington
    General Counsel
  • Ms. Brenda Van Vreeswyk
    Head of Human Resources
  • Mr. Andy Hollman Meyer (Age 40)
    Chief Business Officer

JANX Stock Analysis - Frequently Asked Questions

Should I buy or sell Janux Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JANX shares.
View JANX analyst ratings
or view top-rated stocks.

What is Janux Therapeutics' stock price target for 2024?

6 Wall Street research analysts have issued twelve-month target prices for Janux Therapeutics' stock. Their JANX share price targets range from $35.00 to $100.00. On average, they anticipate the company's stock price to reach $59.60 in the next year. This suggests a possible upside of 14.9% from the stock's current price.
View analysts price targets for JANX
or view top-rated stocks among Wall Street analysts.

How have JANX shares performed in 2024?

Janux Therapeutics' stock was trading at $10.73 on January 1st, 2024. Since then, JANX shares have increased by 383.3% and is now trading at $51.86.
View the best growth stocks for 2024 here
.

Are investors shorting Janux Therapeutics?

Janux Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,750,000 shares, an increase of 20.6% from the March 15th total of 3,110,000 shares. Based on an average daily volume of 711,600 shares, the days-to-cover ratio is presently 5.3 days. Currently, 11.6% of the company's stock are short sold.
View Janux Therapeutics' Short Interest
.

When is Janux Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our JANX earnings forecast
.

How were Janux Therapeutics' earnings last quarter?

Janux Therapeutics, Inc. (NASDAQ:JANX) announced its quarterly earnings data on Friday, March, 8th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.12. The company earned $2.46 million during the quarter, compared to analyst estimates of $0.98 million. Janux Therapeutics had a negative net margin of 721.18% and a negative trailing twelve-month return on equity of 17.88%.

What ETFs hold Janux Therapeutics' stock?

ETFs with the largest weight of Janux Therapeutics (NASDAQ:JANX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Fidelity Disruptive Medicine ETF (FMED).

When did Janux Therapeutics IPO?

Janux Therapeutics (JANX) raised $152 million in an initial public offering on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager.

How do I buy shares of Janux Therapeutics?

Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JANX) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners